UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 103 filers reported holding UROGEN PHARMA LTD in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $29,841 | +25.1% | 2,130 | -7.6% | 0.00% | – |
Q2 2023 | $23,857 | -72.3% | 2,305 | -76.6% | 0.00% | – |
Q1 2022 | $86,000 | +218.5% | 9,857 | +253.4% | 0.00% | – |
Q4 2021 | $27,000 | -42.6% | 2,789 | 0.0% | 0.00% | – |
Q3 2021 | $47,000 | +11.9% | 2,789 | 0.0% | 0.00% | – |
Q2 2021 | $42,000 | -22.2% | 2,789 | 0.0% | 0.00% | – |
Q1 2021 | $54,000 | -6.9% | 2,789 | -13.5% | 0.00% | – |
Q4 2020 | $58,000 | -6.5% | 3,224 | 0.0% | 0.00% | – |
Q3 2020 | $62,000 | -41.0% | 3,224 | -19.9% | 0.00% | – |
Q2 2020 | $105,000 | +43.8% | 4,027 | -1.3% | 0.00% | – |
Q1 2020 | $73,000 | -56.0% | 4,080 | -18.0% | 0.00% | – |
Q4 2019 | $166,000 | +66.0% | 4,973 | +17.6% | 0.00% | – |
Q3 2019 | $100,000 | -28.6% | 4,227 | 0.0% | 0.00% | – |
Q2 2019 | $140,000 | +324.2% | 4,227 | +365.5% | 0.00% | – |
Q1 2019 | $33,000 | +106.2% | 908 | +144.1% | 0.00% | – |
Q4 2018 | $16,000 | -5.9% | 372 | 0.0% | 0.00% | – |
Q3 2018 | $17,000 | -5.6% | 372 | 0.0% | 0.00% | – |
Q2 2018 | $18,000 | – | 372 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |